Novel NS5B Resistance-Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy.
作者信息
Catalli Lisa, Martens Sharon K, Terrault Norah A, Reeves Jacqueline D
机构信息
Division of Gastroenterology/Hepatology University of California, San Francisco San Francisco CA.
Monogram Biosciences LabCorp South San Francisco CA.
出版信息
Clin Liver Dis (Hoboken). 2019 Mar 29;13(3):74-78. doi: 10.1002/cld.768. eCollection 2019 Mar.
Abstract
摘要
相似文献
1
Novel NS5B Resistance-Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy.在索磷布韦/来迪帕司韦治疗失败的情况下出现了新型NS5B耐药相关替代突变。
Clin Liver Dis (Hoboken). 2019 Mar 29;13(3):74-78. doi: 10.1002/cld.768. eCollection 2019 Mar.
2
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎患者的疗效及安全性
J Hepatol. 2017 Apr;66(4):703-710. doi: 10.1016/j.jhep.2016.11.022. Epub 2016 Dec 5.
3
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.HCV NS5A、NS5B 或 NS3 耐药相关取代的流行率以及雷迪帕韦和索磷布韦治疗的结果。
Gastroenterology. 2016 Sep;151(3):501-512.e1. doi: 10.1053/j.gastro.2016.06.002. Epub 2016 Jun 11.
4
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.索磷布韦联合达卡他韦治疗慢性丙型肝炎患者中耐药相关变异体的出现和血清脂质谱的变化。
J Med Virol. 2017 Nov;89(11):1963-1972. doi: 10.1002/jmv.24885. Epub 2017 Jul 25.
5
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.索磷布韦与来迪派韦联合用于治疗丙型肝炎感染。
Expert Rev Gastroenterol Hepatol. 2015;9(12):1483-94. doi: 10.1586/17474124.2015.1111757. Epub 2015 Nov 23.
6
The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.在接受索磷布韦和来迪派韦治疗的 HCV 基因 1 型患者中，NS5A 和 NS5B 耐药相关替换物的共存与病毒学失败相关。
PLoS One. 2018 Jun 1;13(6):e0198642. doi: 10.1371/journal.pone.0198642. eCollection 2018.
7
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.日本丙型肝炎感染患者在3期研究中接受索磷布韦或来迪派韦/索磷布韦治疗方案的耐药性分析
J Viral Hepat. 2016 Oct;23(10):780-8. doi: 10.1111/jvh.12549. Epub 2016 May 15.
8
Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.稳健的 HCV 基因型 3a 感染性细胞培养系统可鉴定对索非布韦耐药的逃逸变异体。
Gastroenterology. 2016 Nov;151(5):973-985.e2. doi: 10.1053/j.gastro.2016.07.013. Epub 2016 Jul 22.
9
Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.来迪派韦索磷布韦作为既往 NS5A 抑制剂方案治疗失败的 HCV 基因 1 型的补救治疗。
J Med Virol. 2017 Jul;89(7):1248-1254. doi: 10.1002/jmv.24767. Epub 2017 Feb 27.
10
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.在真实世界中，对失败于 NS5A 抑制剂的 HCV 患者进行耐药指导的再治疗具有很高的疗效。
J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4.
引用本文的文献
1
Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.埃及慢性丙型肝炎患者中自然发生的 NS5B 耐药相关取代的分布。
PLoS One. 2021 Apr 15;16(4):e0249770. doi: 10.1371/journal.pone.0249770. eCollection 2021.
本文引用的文献
1
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.2018 年丙型肝炎治疗指南更新：美国肝病研究学会-美国传染病学会丙型肝炎病毒感染检测、管理和治疗推荐意见。
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492. doi: 10.1093/cid/ciy585.
2
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.基线耐药相关替换对 ledipasvir/索非布韦或simeprevir/索非布韦治疗 GT1 HCV 感染的疗效的影响及流行率。
Sci Rep. 2018 Feb 16;8(1):3199. doi: 10.1038/s41598-018-21303-2.
3
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.基于索磷布韦治疗后出现NS5B耐药相关替代S282T。
Hepatol Commun. 2017 Jun 22;1(6):538-549. doi: 10.1002/hep4.1060. eCollection 2017 Aug.
4
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.NS5A 耐药相关替换与丙型肝炎病毒基因型 1 患者：流行率和对治疗结局的影响。
J Hepatol. 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. Epub 2017 Jan 18.
5
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎患者的疗效及安全性
J Hepatol. 2017 Apr;66(4):703-710. doi: 10.1016/j.jhep.2016.11.022. Epub 2016 Dec 5.
6
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.来迪派韦-索磷布韦组合疗法对丙型肝炎病毒感染患者的疗效及与持续病毒学应答相关的因素
Gastroenterology. 2016 Dec;151(6):1131-1140.e5. doi: 10.1053/j.gastro.2016.08.004. Epub 2016 Aug 24.
7
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.HCV NS5A、NS5B 或 NS3 耐药相关取代的流行率以及雷迪帕韦和索磷布韦治疗的结果。
Gastroenterology. 2016 Sep;151(3):501-512.e1. doi: 10.1053/j.gastro.2016.06.002. Epub 2016 Jun 11.
8
A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.丙型肝炎病毒非结构蛋白5B的S282和G283与模板链之间复杂的相互作用网络影响对索磷布韦和利巴韦林的敏感性。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2018-27. doi: 10.1128/AAC.02436-15. Print 2016 Apr.
9
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.在索磷布韦单药治疗后复发时检测到携带S282T的一名患者的丙型肝炎病毒种群的演变。
J Viral Hepat. 2015 Nov;22(11):871-81. doi: 10.1111/jvh.12405. Epub 2015 Mar 18.
10
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.在2期和3期临床试验中，接受索磷布韦治疗的1-6型丙型肝炎病毒感染受试者耐药性发生频率较低。
Clin Infect Dis. 2014 Dec 15;59(12):1666-74. doi: 10.1093/cid/ciu697. Epub 2014 Sep 28.
Zotero 插件